Attached files

file filename
EX-32.2 - EXHIBIT 32.2 - ELITE PHARMACEUTICALS INC /NV/tv495946_ex32-2.htm
EX-32.1 - EXHIBIT 32.1 - ELITE PHARMACEUTICALS INC /NV/tv495946_ex32-1.htm
EX-31.2 - EXHIBIT 31.2 - ELITE PHARMACEUTICALS INC /NV/tv495946_ex31-2.htm
EX-31.1 - EXHIBIT 31.1 - ELITE PHARMACEUTICALS INC /NV/tv495946_ex31-1.htm
EX-21 - EXHIBIT 21 - ELITE PHARMACEUTICALS INC /NV/tv495946_ex21.htm
EX-10.60 - EXHIBIT 10.60 - ELITE PHARMACEUTICALS INC /NV/tv495946_ex10-60.htm
10-K - FORM 10-K - ELITE PHARMACEUTICALS INC /NV/tv495946_10k.htm

 

 EXHIBIT 23.1

 

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 

We consent to the incorporation by reference in the following documents of our reports dated June 14, 2018, relating to the consolidated financial statements of Elite Pharmaceuticals, Inc. and Subsidiary, and the effectiveness of internal control over financial reporting of Elite Pharmaceuticals, Inc. and Subsidiary, included in the Annual Report on Form 10-K of the Company for the year ended March 31, 2018.

 

Registration Statement No. 333-217866 on Form S-3

Registration Statement No. 333-197694 on Form S-8

Registration Statement No. 333-163907 on Form S-8

Registration Statement No. 333-132140 on Form S-8

Registration Statement No. 333-118524 on Form S-8

 

Buchbinder Tunick & Company LLP

 

 
 
Wayne, New Jersey  
June 14, 2018